Communiqués MBX Biosciences, Inc.

Actions

MBX

US55287L1017

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 08/05/2026			Varia. 5j.	Varia. 1 janv.
40,96 ^USD	+18,02 %		+37,56 %	+29,88 %

07/05	MBX Biosciences, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
22/04	PMV Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration, effectifs au 4 juin 2026	CI

Communiqués

07/05	MBX Biosciences : Company Overview - May 2026	PU
07/05	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights	AQ
07/05	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award	AQ
23/04	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio	AQ
03/04	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/03	MBX Biosciences : Company Overview - March 2026	PU
12/03	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
10/03	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer	AQ
09/03	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism	AQ
23/02	MBX Biosciences to Participate in Upcoming March Investor Conferences	AQ
11/02	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
22/01	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair	AQ
14/01	MBX Biosciences : Company Overview - January 2025	PU
11/01	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
15/12	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
18/11	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference	AQ
06/11	MBX Biosciences : Company Overview - November 2025	PU
06/11	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
20/10/25	MBX Biosciences to Participate in November Investor Conferences	AQ
29/09/25	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum	AQ
25/09/25	MBX Biosciences Announces Pricing of Upsized Public Offering	AQ
22/09/25	MBX Biosciences Announces Proposed Public Offering	AQ
22/09/25	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension	AQ
19/09/25	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22	AQ
04/09/25	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity	AQ